Theriva Biologics (TOVX) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Universe Pharmaceuticals (UPC) over the past year, losing 45.5% versus a loss of 68.2%. Over five years, TOVX leads with a -99.9% price change compared with -100.0% for UPC. Theriva Biologics is the larger company by market cap ($5.5 million vs $5.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TOVX | UPC |
|---|---|---|
| Share price | $0.12 | $1.08 |
| Market cap | $5.51M | $5.43M |
| 1-day change | -6.25% | -20.59% |
| YTD return | -42.86% | -71.65% |
| 1-year return | -45.45% | -68.24% |
| 5-year return | -99.86% | -99.99% |
| P/E ratio (TTM) | 0.10 | — |
| EPS (TTM) | $1.15 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.86B |
| Revenue growth (YoY) | — | -22.44% |
| Net income (latest FY) | $-23.74M | $-3.67B |
| Gross margin | — | 35.28% |
| Operating margin | — | -16.33% |
| Net margin | — | -20.56% |
| 52-week high | $0.49 | $17.96 |
| 52-week low | $0.12 | $1.05 |
| Distance from 52-week high | -75.51% | -93.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +1983.33% | — |
| Average volume | 2.02M | 176.76K |
| Shares outstanding | 45.89M | 5.01M |
| Employees | 15 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed UPC by 22.8 percentage points over the past year.
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
TOVX vs UPC FAQ
Which is bigger, Theriva Biologics or Universe Pharmaceuticals?
Theriva Biologics (TOVX) is larger, with a market capitalization of $5.51M compared with $5.43M for Universe Pharmaceuticals (UPC).
Which stock has performed better over the past year, TOVX or UPC?
TOVX returned -45.45% over the past 12 months, compared with -68.24% for UPC (price return, excluding dividends). Past performance does not predict future results.
Are Theriva Biologics and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.